Recent News

• 04.21.2025 - Alumis and ACELYRIN Announce Amended Merger Agreement
• 04.21.2025 - Alumis and ACELYRIN Announce Amended Merger Agreement
• 04.04.2025 - Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
• 04.04.2025 - Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
• 03.25.2025 - Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
• 03.25.2025 - Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
• 03.19.2025 - Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
• 03.19.2025 - Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Recent Filings

• 04.04.2025 - 425 Prospectuses and communications, business combinations
• 04.04.2025 - EFFECT Notice of Effectiveness
• 04.04.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.02.2025 - S-4/A Registration of securities, business combinations
• 03.27.2025 - S-4 Registration of securities, business combinations
• 03.25.2025 - 425 Prospectuses and communications, business combinations
• 03.25.2025 - EX-99.1 EX-99.1
• 03.25.2025 - 8-K Current report